X
ABBV icon

Xponance’s AbbVie ABBV Stock Holding History

Xponance’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.3M Sell
350,912
-161,033
-31% -$34.6M 0.54% 29
2026
Q1 		$111M Buy
511,945
+32,393
+7% +$7.19M 0.79% 19
2025
Q4 		$110M Buy
479,552
+15,898
+3% +$3.62M 0.82% 15
2025
Q3 		$107M Buy
463,654
+12,379
+3% +$2.52M 0.85% 18
2025
Q2 		$83.8M Buy
451,275
+107,804
+31% +$20M 0.7% 19
2025
Q1 		$72M Buy
343,471
+4,597
+1% +$894K 0.7% 19
2024
Q4 		$60.2M Sell
338,874
-631
-0.2% -$116K 0.55% 24
2024
Q3 		$67M Buy
339,505
+6,919
+2% +$1.29M 0.65% 20
2024
Q2 		$57M Sell
332,586
-86,817
-21% -$14.4M 0.58% 23
2024
Q1 		$76.4M Buy
419,403
+6,803
+2% +$1.17M 0.8% 17
2023
Q4 		$63.9M Buy
412,600
+7,001
+2% +$1.02M 0.77% 18
2023
Q3 		$60.5M Buy
405,599
+3,109
+0.8% +$456K 0.82% 16
2023
Q2 		$54.2M Buy
402,490
+4,966
+1% +$728K 0.72% 17
2023
Q1 		$63.4M Buy
397,524
+8,004
+2% +$1.22M 0.93% 13
2022
Q4 		$63M Buy
389,520
+34,407
+10% +$5.28M 1.02% 12
2022
Q3 		$47.7M Buy
355,113
+25,491
+8% +$3.66M 0.92% 12
2022
Q2 		$50.5M Sell
329,622
-8,602
-3% -$1.31M 1.01% 11
2022
Q1 		$54.8M Buy
338,224
+28,895
+9% +$4.2M 0.91% 12
2021
Q4 		$41.9M Buy
309,329
+24,162
+8% +$2.85M 0.66% 21
2021
Q3 		$30.8M Sell
285,167
-50,291
-15% -$5.75M 0.58% 23
2021
Q2 		$37.8M Buy
335,458
+10,375
+3% +$1.17M 0.69% 16
2021
Q1 		$35.2M Sell
325,083
-136
-0% -$14.5K 0.75% 19
2020
Q4 		$34.8M Buy
325,219
+1,752
+0.5% +$168K 0.76% 19
2020
Q3 		$28.3M Sell
323,467
-17,198
-5% -$1.62M 0.7% 24
2020
Q2 		$33.4M Buy
+340,665
New +$30M 0.86% 18

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Xponance's ABBV Position: Q2 2026 in Review

Xponance reduced its AbbVie (ABBV) stake by 31% in Q2 2026, selling an estimated $34.6M and leaving 350,912 shares worth $88.3M. The position accounts for 0.54% of the portfolio, ranked #29.

Xponance first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. The position peaked at $111M in Q1 2026. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Xponance held 350,912 shares of AbbVie worth $88.3M as of Q2 2026.
  • Xponance sold 161,033 AbbVie shares in Q2 2026, an estimated $34.6M.
  • AbbVie made up 0.54% of Xponance's portfolio in Q2 2026, its #29 holding.
  • Xponance first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • Xponance's AbbVie position peaked at $111M in Q1 2026.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.